Alkermes Stock Price, News & Analysis (NASDAQ:ALKS)

$58.60 +2.05 (+3.63 %)
(As of 02/25/2018 04:54 AM ET)
Previous Close$58.60
Today's Range$56.00 - $61.67
52-Week Range$46.42 - $71.22
Volume937,105 shs
Average Volume1.19 million shs
Market Capitalization$9.34 billion
P/E Ratio-62.34
Dividend YieldN/A

About Alkermes (NASDAQ:ALKS)

Alkermes logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research


Debt-to-Equity Ratio0.23%
Current Ratio2.78%
Quick Ratio2.72%


Trailing P/E Ratio-62.3404255319149
Forward P/E Ratio-73.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$903.37 million
Price / Sales9.99
Cash Flow$0.29 per share
Price / Cash205.12
Book Value$7.81 per share
Price / Book7.50


Trailing EPS($0.94)
Net Income$-157,950,000.00
Net Margins-17.48%
Return on Equity-4.32%
Return on Assets-2.97%


Outstanding Shares154,010,000

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) released its quarterly earnings data on Wednesday, February, 14th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.01) by $0.32. The company earned $275.37 million during the quarter, compared to the consensus estimate of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The firm's revenue was up 29.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.02 earnings per share. View Alkermes' Earnings History.

When will Alkermes make its next earnings announcement?

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Alkermes.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share (EPS) guidance of ($0.23-0.03) for the period, compared to the Thomson Reuters consensus estimate of $0.73. The company issued revenue guidance of $975 million-1.025 billion, compared to the consensus revenue estimate of $1.01 billion.

Where is Alkermes' stock going? Where will Alkermes' stock price be in 2018?

10 equities research analysts have issued 1-year price objectives for Alkermes' stock. Their forecasts range from $50.00 to $81.00. On average, they expect Alkermes' share price to reach $65.00 in the next twelve months. View Analyst Ratings for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:

  • 1. Cantor Fitzgerald analysts commented, "Story still mainly about fate of ALKS 5461. With NDA recently filed, management believes a potential FDA Adcom and regulatory action could occur by YE18. The hiring of an additional 200 sales reps in 2018 disclosed on the 4Q17 results call seems aggressive to us given uncertainty about approval (unless intended to portray confidence), though we are mindful that they could be shifted to Vivitrol/Aristada. We suppose, too, that the expansion could be done in a step- wise manner." (2/20/2018)
  • 2. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada are primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being- FDA review of the ALKS 5461 new drug application (NDA) for treatment of major depressive disorder, the phase III data readout for ALKS 3831 in schizophrenia, submission of the ALKS 8700 NDA and phase I data read-out for ALKS 4230. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company’s partners. Given its history of pipeline setbacks, any obstacle in the process of development of the candidates could weigh heavily on the stock. Moreover, Alkermes’ shares have underperformed the industry year to date. Estimates have increased ahead of the Q4 earnings results." (2/5/2018)
  • 3. Cowen Inc analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)

Who are some of Alkermes' key competitors?

Who are Alkermes' key executives?

Alkermes' management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer (Age 55)
  • Shane M. Cooke, President (Age 54)
  • James M. Frates, Chief Financial Officer, Senior Vice President, Treasurer (Age 49)
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary (Age 58)
  • Elliot W. Ehrich M.D., Executive Vice President - Science and Therapeutics (Age 57)
  • Iain M. Brown, Senior Vice President - Finance, Chief Accounting Officer (Age 48)
  • David Joseph Gaffin, Senior Vice President, Chief Legal Officer (Age 45)

Who owns Alkermes stock?

Alkermes' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (11.35%), BlackRock Inc. (6.87%), Woodford Investment Management Ltd (4.93%), Goldman Sachs Group Inc. (2.64%), Franklin Resources Inc. (2.05%) and Geode Capital Management LLC (0.87%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.

Who sold Alkermes stock? Who is selling Alkermes stock?

Alkermes' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Tocqueville Asset Management L.P., Millennium Management LLC, Bank of New York Mellon Corp, Frontier Capital Management Co. LLC, Macquarie Group Ltd., Deutsche Bank AG and KBC Group NV. Company insiders that have sold Alkermes company stock in the last year include Elliot Ehrich, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes.

Who bought Alkermes stock? Who is buying Alkermes stock?

Alkermes' stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Amundi Pioneer Asset Management Inc., Woodford Investment Management Ltd, State of Wisconsin Investment Board, Two Sigma Investments LP, Two Sigma Advisers LP, Tekla Capital Management LLC and AXA. View Insider Buying and Selling for Alkermes.

How do I buy Alkermes stock?

Shares of Alkermes can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes' stock price today?

One share of Alkermes stock can currently be purchased for approximately $58.60.

How big of a company is Alkermes?

Alkermes has a market capitalization of $9.34 billion and generates $903.37 million in revenue each year. The company earns $-157,950,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Alkermes employs 1,750 workers across the globe.

How can I contact Alkermes?

Alkermes' mailing address is Connaught HSE, 1 Burlington Road, DUBLIN, MA 00000, Ireland. The company can be reached via phone at +353-1-7728000 or via email at [email protected]

MarketBeat Community Rating for Alkermes (ALKS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alkermes (NASDAQ:ALKS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.402.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $65.00$64.50$64.50$63.63
Price Target Upside: 14.94% upside28.08% upside29.39% upside26.19% upside

Alkermes (NASDAQ:ALKS) Consensus Price Target History

Price Target History for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ:ALKS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Morgan StanleyReiterated RatingOverweight -> Equal Weight$60.00 -> $67.00MediumView Rating Details
2/22/2018Jefferies GroupDowngradeBuy -> Hold$63.19 -> $66.00HighView Rating Details
2/20/2018Cantor FitzgeraldReiterated RatingHold$50.00MediumView Rating Details
2/16/2018Credit Suisse GroupBoost Price TargetOutperform$66.00 -> $70.00HighView Rating Details
2/15/2018CitigroupSet Price TargetHold$62.00HighView Rating Details
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
10/26/2017BarclaysSet Price TargetHold$50.00N/AView Rating Details
10/21/2017MizuhoSet Price TargetBuy$81.00N/AView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
4/28/2017CowenReiterated RatingBuyLowView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
(Data available from 2/25/2016 forward)


Alkermes (NASDAQ:ALKS) Earnings History and Estimates Chart

Earnings by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018($0.08)N/AView Earnings Details
2/14/2018Q4 17($0.01)$0.31$251.23 million$275.37 millionViewListenView Earnings Details
10/26/20179/30/2017($0.01)$0.03$231.29 million$217.40 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.01)$0.01$216.54 million$218.80 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.15)($0.08)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.14)($0.14)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.15)($0.15)ViewN/AView Earnings Details
2/4/2010Q4 2009($0.14)($0.07)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.10)($0.09)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.11)($0.11)ViewN/AView Earnings Details
5/21/2009Q1 2009($0.13)($0.14)ViewN/AView Earnings Details
2/5/2009Q4 2008$1.20$1.18ViewN/AView Earnings Details
11/6/2008Q3 2008($0.01)$0.02ViewN/AView Earnings Details
8/7/2008Q2 2008$0.17$0.31ViewN/AView Earnings Details
5/22/2008Q1 2008$0.01($0.07)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.01)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Alkermes (NASDAQ:ALKS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181$0.07$0.07$0.07
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.08)($0.08)($0.08)
(Earnings estimates data provided by Zacks Investment Research)


Dividend History for Alkermes (NASDAQ:ALKS)

No dividend announcements for this company have been tracked by

Insider Trades

Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.34%
Insider Trades by Quarter for Alkermes (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Alkermes (NASDAQ ALKS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Mark StejbachSVPSell10,880$70.50$767,040.0054,893View SEC Filing  
2/2/2018Shane CookeInsiderSell72,793$60.55$4,407,616.15147,501View SEC Filing  
2/1/2018Paul J MitchellDirectorSell1,000$56.77$56,770.009,000View SEC Filing  
1/29/2018Shane CookeInsiderSell3,300$60.00$198,000.0076,408View SEC Filing  
1/26/2018Shane CookeInsiderSell1,700$60.02$102,034.0076,408View SEC Filing  
1/11/2018Shane CookeInsiderSell6,207$60.22$373,785.5480,915View SEC Filing  
1/2/2018Paul J MitchellDirectorSell1,000$54.99$54,990.009,000View SEC Filing  
12/29/2017Iain Michael BrownSVPSell10,652$54.81$583,836.12View SEC Filing  
12/29/2017Iain Michael BrownCAOSell10,652$54.81$583,836.1216,943View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.80View SEC Filing  
12/1/2017Paul J MitchellDirectorSell1,000$51.98$51,980.009,000View SEC Filing  
11/29/2017James M FratesSVPSell20,932$50.51$1,057,275.32164,971View SEC Filing  
11/8/2017James M. FratesSVPSell20,932$47.58$995,944.56View SEC Filing  
11/2/2017Richard F PopsDirectorSell50,000$48.87$2,443,500.00View SEC Filing  
11/1/2017Michael J LandineSVPSell15,000$48.71$730,650.00178,693View SEC Filing  
10/2/2017Paul J MitchellDirectorSell1,500$50.64$75,960.00View SEC Filing  
9/11/2017Kathryn L BibersteinCAOSell13,566$51.29$695,800.1470,455View SEC Filing  
9/1/2017Paul J MitchellDirectorSell1,500$50.77$76,155.009,500View SEC Filing  
8/1/2017Paul J MitchellDirectorSell1,500$54.91$82,365.009,500View SEC Filing  
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.009,500View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.0084,708View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.009,500View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00649,137View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00167,370View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00680,406View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00172,370View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00655,406View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.0078,448View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.0065,071View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.0069,904View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.009,500View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.0072,148View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.3074,948View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.0072,048View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.0072,048View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.0066,071View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00144,053View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.007,156View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.0073,068View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.009,500View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.0049,657View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.009,500View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.5662,640View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.6934,662View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.5064,494View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.0060,140View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.6536,615View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.0066,487View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.0011,156View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.0027,207View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.009,500View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.7037,277View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.0057,640View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00127,342View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.4564,623View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.8543,687View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.0038,687View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00165,659View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00638,962View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00638,962View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.0010,000View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.0046,477View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.0050,311View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.4422,816View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.0055,311View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.9225,696View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.0010,000View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.0010,000View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.0546,111View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.0010,000View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.0010,000View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.0010,000View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75159,419View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50595,247View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.3651,822View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.6852,642View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00601,497View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.0010,000View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00601,497View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00581,307View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.0010,000View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.0015,000View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.008,000View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.0035,156View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.0019,564View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.0050,240View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00141,324View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00553,497View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.0019,564View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00141,324View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00553,497View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.0037,156View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.0050,240View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.0019,964View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.0039,156View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.7838,689View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.0050,240View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.0051,357View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.0041,156View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.0040,640View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00138,680View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00542,917View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.0048,713View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00138,680View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00542,917View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.0043,156View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.0040,640View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.2220,992View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.0054,192View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.141,321View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.0023,370View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.0042,904View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.3020,992View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.0090,281View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.0053,756View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.008,000View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.0036,644View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.008,000View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.0036,644View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.001,600View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.0093,644View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.1016,579View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.008,000View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.9816,579View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.2516,579View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.0048,301View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.0093,644View SEC Filing  
(Data available from 1/1/2013 forward)


Alkermes (NASDAQ ALKS) News Headlines

Alkermes Plc (ALKS) Stake Decreased by UBS Asset Management Americas Inc.Alkermes Plc (ALKS) Stake Decreased by UBS Asset Management Americas Inc. - February 24 at 10:22 AM
Analyst Ratings for Vanda Pharmaceuticals and Peers in FebruaryAnalyst Ratings for Vanda Pharmaceuticals and Peers in February - February 24 at 9:00 AM
Aperio Group LLC Acquires 6,072 Shares of Alkermes Plc (ALKS)Aperio Group LLC Acquires 6,072 Shares of Alkermes Plc (ALKS) - February 24 at 5:02 AM
Morgan Stanley Raises Alkermes (ALKS) Price Target to $67.00Morgan Stanley Raises Alkermes (ALKS) Price Target to $67.00 - February 23 at 8:00 PM
Alkermes Plc (ALKS) Expected to Post Earnings of -$0.04 Per ShareAlkermes Plc (ALKS) Expected to Post Earnings of -$0.04 Per Share - February 23 at 3:14 AM
Alkermes Plc (ALKS) SVP Sells $767,040.00 in StockAlkermes Plc (ALKS) SVP Sells $767,040.00 in Stock - February 21 at 9:24 PM
Alkermes (ALKS) "Hold" Rating Reaffirmed at Cantor FitzgeraldAlkermes' (ALKS) "Hold" Rating Reaffirmed at Cantor Fitzgerald - February 20 at 5:22 PM
Alkermes Sets Itself Up for a "Transformative" 2018Alkermes Sets Itself Up for a "Transformative" 2018 - February 20 at 8:53 AM
Jefferies Group Comments on Alkermes Plcs FY2022 Earnings (ALKS)Jefferies Group Comments on Alkermes Plc's FY2022 Earnings (ALKS) - February 19 at 9:34 AM
Alkermes (ALKS) Given New $70.00 Price Target at Credit Suisse GroupAlkermes (ALKS) Given New $70.00 Price Target at Credit Suisse Group - February 16 at 3:24 PM
Alkermes PLC (ALKS) Files 10-K for the Fiscal Year Ended on December 31, 2017Alkermes PLC (ALKS) Files 10-K for the Fiscal Year Ended on December 31, 2017 - February 16 at 8:55 AM
Alkermes (ALKS) PT Set at $62.00 by CitigroupAlkermes (ALKS) PT Set at $62.00 by Citigroup - February 15 at 11:52 PM
Credit Suisse Group Reiterates "$66.00" Price Target for Alkermes (ALKS)Credit Suisse Group Reiterates "$66.00" Price Target for Alkermes (ALKS) - February 15 at 11:22 PM
Alkermes (ALKS) Beats Q4 Earnings, Revenue EstimatesAlkermes (ALKS) Beats Q4 Earnings, Revenue Estimates - February 15 at 4:47 PM
Alkermes plc (ALKS) Tops Q4 EPS by 7c, Offers GuidanceAlkermes plc (ALKS) Tops Q4 EPS by 7c, Offers Guidance - February 15 at 8:33 AM
Do Options Traders Know Something About Alkermes (ALKS) Stock We Dont?Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? - February 14 at 4:57 PM
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? - February 14 at 4:57 PM
Here's Why Alkermes Spiked TodayHere's Why Alkermes Spiked Today - February 14 at 4:57 PM
Alkermes (ALKS) Issues FY18 Earnings GuidanceAlkermes (ALKS) Issues FY18 Earnings Guidance - February 14 at 9:24 AM
Alkermes narrows loss by 54% to top estimatesAlkermes narrows loss by 54% to top estimates - February 14 at 9:21 AM
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018 - February 14 at 9:21 AM
Alkermes Appoints Shane Cooke to Board of DirectorsAlkermes Appoints Shane Cooke to Board of Directors - February 14 at 9:21 AM
Alkermes (ALKS) Issues  Earnings ResultsAlkermes (ALKS) Issues Earnings Results - February 14 at 9:04 AM
Why Earnings Season Could Be Great for Alkermes (ALKS)Why Earnings Season Could Be Great for Alkermes (ALKS) - February 12 at 9:19 AM
Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial ResultsAlkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results - February 8 at 8:44 AM
$0.21 EPS Expected for Alkermes Plc (ALKS) This Quarter$0.21 EPS Expected for Alkermes Plc (ALKS) This Quarter - February 6 at 3:18 AM
Alkermes (ALKS) Scheduled to Post Earnings on TuesdayAlkermes (ALKS) Scheduled to Post Earnings on Tuesday - February 6 at 3:12 AM
This Explains Why Alkermes Plc Is Falling TodayThis Explains Why Alkermes Plc Is Falling Today - February 5 at 4:46 PM
Alkermes Reaches Analyst Target Price - NasdaqAlkermes Reaches Analyst Target Price - Nasdaq - February 5 at 4:13 PM
Alkermes (ALKS) Upgraded to "Buy" by Zacks Investment ResearchAlkermes (ALKS) Upgraded to "Buy" by Zacks Investment Research - February 5 at 1:42 PM
5 Opioid Treatment Stocks5 Opioid Treatment Stocks - February 5 at 9:19 AM
Analyst Recommendations for Biogen in January 2018Analyst Recommendations for Biogen in January 2018 - February 5 at 9:19 AM
Strength Seen in Alkermes (ALKS): Stock Soars 8.7%Strength Seen in Alkermes (ALKS): Stock Soars 8.7% - February 5 at 9:19 AM
Alkermes Plc (ALKS) Receives Consensus Rating of "Hold" from AnalystsAlkermes Plc (ALKS) Receives Consensus Rating of "Hold" from Analysts - February 3 at 9:40 AM
Insider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of StockInsider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of Stock - February 2 at 10:02 PM
Alkermes Plc (ALKS) Insider Shane Cooke Sells 72,793 SharesAlkermes Plc (ALKS) Insider Shane Cooke Sells 72,793 Shares - February 2 at 9:12 PM
Alkermes (ALKS) Downgraded by Zacks Investment Research to "Hold"Alkermes (ALKS) Downgraded by Zacks Investment Research to "Hold" - February 2 at 7:48 PM
Alkermes plc (ALKS) Submits NDA for ALKS 5461 For Adjunctive Treatment Of MDDAlkermes plc (ALKS) Submits NDA for ALKS 5461 For Adjunctive Treatment Of MDD - February 1 at 9:26 AM
Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive DisorderAlkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder - January 31 at 4:16 PM
Insider Selling: Alkermes Plc (ALKS) Insider Sells 3,300 Shares of StockInsider Selling: Alkermes Plc (ALKS) Insider Sells 3,300 Shares of Stock - January 30 at 12:14 AM
Shane Cooke Sells 1,700 Shares of Alkermes Plc (ALKS) StockShane Cooke Sells 1,700 Shares of Alkermes Plc (ALKS) Stock - January 30 at 12:14 AM
Alkermes (ALKS) Upgraded to "Hold" by BidaskClubAlkermes (ALKS) Upgraded to "Hold" by BidaskClub - January 27 at 10:16 AM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc (ALKS) & Lead Plaintiff Deadline- January 22, 2018 - January 22 at 6:02 PM
DEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKSDEADLINE ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS - January 22 at 6:02 PM
Alkermes Plc (ALKS) Expected to Post Quarterly Sales of $247.52 MillionAlkermes Plc (ALKS) Expected to Post Quarterly Sales of $247.52 Million - January 22 at 10:08 AM
Alkermes (ALKS) vs. Corvus Pharmaceuticals (CRVS) Financial ContrastAlkermes (ALKS) vs. Corvus Pharmaceuticals (CRVS) Financial Contrast - January 20 at 1:16 PM
Alkermes (ALKS) Stock Rating Lowered by BidaskClubAlkermes (ALKS) Stock Rating Lowered by BidaskClub - January 20 at 12:33 PM
Alkermes Plc (ALKS) Expected to Post Earnings of $0.18 Per ShareAlkermes Plc (ALKS) Expected to Post Earnings of $0.18 Per Share - January 20 at 5:22 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKSSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018 - ALKS - January 19 at 11:08 AM

SEC Filings

Alkermes (NASDAQ:ALKS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement


Alkermes (NASDAQ ALKS) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.